JACC: Basic to Translational Science (Aug 2017)

The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure

  • Najah Harouki, BS,
  • Lionel Nicol, PhD,
  • Isabelle Remy-Jouet, PhD,
  • Jean-Paul Henry, BS,
  • Anais Dumesnil, BS,
  • Annie Lejeune, BS,
  • Sylvanie Renet, BS,
  • Francesca Golding, BS,
  • Zoubir Djerada, PhD,
  • Didier Wecker, PhD,
  • Virginie Bolduc, PhD,
  • Muriel Bouly, PhD,
  • Jerome Roussel, PhD,
  • Vincent Richard, PhD,
  • Paul Mulder, PhD

DOI
https://doi.org/10.1016/j.jacbts.2017.06.005
Journal volume & issue
Vol. 2, no. 4
pp. 418 – 430

Abstract

Read online

This study reports preclinical data showing that the interleukin (IL)-1β modulation is a new promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial infarction, administration of the IL-1β antibody gevokizumab improves ‘surrogate’ markers of survival (i.e., left ventricular remodeling, hemodynamics, and function as well as coronary function). However, whether IL-1β modulation per se or in combination with standard treatments of heart failure improves long-term outcome in human heart failure remains to be determined.

Keywords